Drug Trial Radar · NCT06317805
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Dec 6, 2023
Primary completion
Jun 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- AOP Orphan Pharmaceuticals AGIndustry
- Sponsor type
- Industry
- Collaborators
- ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial s.r.o.; GCP-Service International Ltd. & Co. KG
- First posted
- Mar 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy (oral ERA + oral PDE-5i) in pulmonary arterial hypertension (PAH) patients (group I) with intermediate-high risk or patients with intermediate-low risk with severe hemodynamic impairment at baseline in a prospective, randomized, unblinded setting with scope of increasing evidence for optimization of therapy concepts in PAH. The effect of initial triple combination therapy vs initial double oral therapy (standard of care (SoC)) will be measured by primary endpoint: (non)response to the assigned treatment.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Generic treprostinil sodium + Standard of Care (Double Oral)Drug
Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
Standard of Care - Double OralDrug
All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients achieving (non-)response status to the assigned treatment in terms of achievement of low-risk statusTime frame: between week 12 and week 48 from baseline (BL)
Locations
28 sites in 12 countries. Site status is shown where the registry gives one.
Instituto Neumonológico del Sur (INEUS)
Bahía Blanca, Argentina · Active not recruiting
Centro Gallego de Buenos Aires
Buenos Aires, Argentina · Active not recruiting
Fundación Favaloro
Buenos Aires, Argentina · Active not recruiting
Hospital Británico de Buenos Aires
Buenos Aires, Argentina · Active not recruiting
Hospital Italiano de Buenos Aires (HIBA)
Buenos Aires, Argentina · Active not recruiting
Hospital Ramos Mejia
Buenos Aires, Argentina · Active not recruiting
Sanatorio Mitre de Buenos Aires
Buenos Aires, Argentina · Active not recruiting
Centro Médico Capital
La Plata, Argentina · Active not recruiting
Ordensklinikum Linz
Linz, Austria · Recruiting
Medical University Vienna
Vienna, Austria · Recruiting
Fakultní Nemocnice Olomouc
Olomouc, Czechia · Not yet recruiting
Všeobecná fakultní nemocnice v Praze
Prague, Czechia · Not yet recruiting
Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris
Paris, France · Not yet recruiting
Hôpitaux Universitaires de Strasbourg
Strasbourg, France · Not yet recruiting
DRK Kliniken Berlin Westend
Berlin, Germany · Not yet recruiting
University Hospital Carl Gustav Carus of Technical University Dresden
Dresden, Germany · Not yet recruiting
Universitätsmedizin Greifswald
Greifswald, Germany · Not yet recruiting
Gottsegen National Cardiovascular lnstitute
Budapest, Hungary · Not yet recruiting
Medical University of Szeged
Szeged, Hungary · Not yet recruiting
Sapienza University of Rome
Rome, Italy · Recruiting
John Paul II Hospital Krakow
Krakow, Poland · Not yet recruiting
Fryderyk Chopin Hospital in European Health Centre Otwock
Otwock, Poland · Not yet recruiting
Centro Hospitalar Lisboa Norte - Santa Maria University Hospital
Lisbon, Portugal · Not yet recruiting
Emergency Institute for Cardiovascular Diseases Prof. Dr. C.C.Iliescu
Bucharest, Romania · Not yet recruiting
Emergency Clinical County Hospital of Targu Mures
Târgu Mureş, Romania · Not yet recruiting
Hospital Clinic of Barcelona
Barcelona, Spain · Not yet recruiting
Hospital Ramon y Cajal
Madrid, Spain · Not yet recruiting
Hospital Maciel
Montevideo, Uruguay · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.